NateraNTRA
NASDAQ · USA · Segment 6 of 8 in the Medicine, pharma & life science value chain: Diagnostics
Molecular and genetic diagnostics across prenatal screening, oncology and transplantation.
Diagnostics: Tests, imaging and assays that support clinical decision-making.
Key metrics
Market cap
$40.2B
Price
$270.31
Today
−4.1%
Return YTD
+23.0%
Return 1Y
+74.3%
P/E
—
P/S
16.1
P/B
22.7
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Prenatal screening (Panorama)
- Oncology testing (Signatera)
- Transplant diagnostics
Competitors
- Guardant Health
- Exact Sciences
- Myriad Genetics
Risks
- Reimbursement & coverage
- Patent disputes
Same segment: Diagnostics
See where Natera sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →